Profile data is unavailable for this security.
About the company
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to advancing antibody complement therapeutics to treat severe autoimmune diseases. The Company is dedicated to designing and delivering monoclonal antibodies with improved selectivity and potency. The Company has initiated a Phase 2 trial of DNTH103, a potential active C1s inhibitor, in generalized Myasthenia Gravis and plans to initiate additional Phase 2 trials in other neuromuscular indications, including Multifocal Motor Neuropathy and Chronic Inflammatory Demyelinating Polyneuropathy. Its product candidate, DNTH103, is a clinical-stage, highly potent, highly selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of the C1s complement protein. DNTH103 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic (PK) profile.
- Revenue in USD (TTM)3.22m
- Net income in USD-50.21m
- Incorporated2015
- Employees53.00
- LocationDianthus Therapeutics Inc300 Technology Square, 8Th FloorCAMBRIDGE 02139United StatesUSA
- Phone+1 (857) 201-2700
- Fax+1 (302) 655-5049
- Websitehttps://dianthustx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Castle Biosciences Inc | 250.73m | -30.80m | 669.20m | 610.00 | -- | 1.66 | -- | 2.67 | -1.15 | -1.15 | 9.28 | 14.59 | 0.5664 | 8.01 | 7.12 | 411,024.60 | -6.96 | -9.43 | -7.48 | -10.17 | 80.58 | 80.58 | -12.28 | -28.46 | 9.02 | -- | 0.0243 | -- | 60.38 | 57.35 | 14.41 | -- | 117.94 | -- |
Mineralys Therapeutics Inc | 0.00 | -90.80m | 671.01m | 28.00 | -- | 2.05 | -- | -- | -2.18 | -2.18 | 0.00 | 6.61 | 0.00 | -- | -- | 0.00 | -27.78 | -- | -29.11 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -141.28 | -- | -- | -- |
Prime Medicine Inc | 0.00 | -198.13m | 673.36m | 234.00 | -- | 4.11 | -- | -- | -2.17 | -2.17 | 0.00 | 1.37 | 0.00 | -- | -- | 0.00 | -71.51 | -- | -84.13 | -- | -- | -- | -- | -- | -- | -85.97 | 0.00 | -- | -- | -- | -39.52 | -- | -- | -- |
Wave Life Sciences Ltd | 112.91m | -61.67m | 687.43m | 266.00 | -- | 27.08 | -- | 6.09 | -0.5152 | -0.5152 | 0.9985 | 0.2719 | 0.4494 | -- | -- | 424,488.70 | -24.54 | -56.98 | -60.43 | -102.38 | -- | -- | -54.61 | -353.20 | -- | -- | -- | -- | 3,005.10 | 51.04 | 64.46 | -- | -35.44 | -- |
Hillevax Inc | 0.00 | -143.51m | 688.14m | 90.00 | -- | 2.88 | -- | -- | -2.33 | -2.33 | 0.00 | 4.81 | 0.00 | -- | -- | 0.00 | -46.66 | -- | -50.34 | -- | -- | -- | -- | -- | -- | -- | 0.0963 | -- | -- | -- | 22.68 | -- | -- | -- |
Phibro Animal Health Corp | 999.56m | 13.16m | 710.84m | 1.92k | 54.02 | 2.63 | 14.59 | 0.7112 | 0.3249 | 0.3249 | 24.68 | 6.67 | 1.03 | 2.42 | 6.37 | 520,606.30 | 1.35 | 5.46 | 1.66 | 6.83 | 30.33 | 31.41 | 1.32 | 5.11 | 1.67 | 2.26 | 0.6427 | 42.99 | 3.78 | 3.59 | -33.69 | -13.56 | 22.80 | 3.71 |
Dianthus Therapeutics Inc | 3.22m | -50.21m | 712.88m | 53.00 | -- | 1.91 | -- | 221.12 | -3.20 | -3.20 | 0.2721 | 12.70 | 0.0138 | -- | -- | 60,830.19 | -21.56 | -41.40 | -22.27 | -44.70 | -- | -- | -1,557.51 | -12,132.27 | -- | -- | 0.00 | -- | -- | -- | 43.04 | -- | -57.21 | -- |
SAGE Therapeutics Inc | 91.06m | -503.14m | 716.17m | 487.00 | -- | 1.01 | -- | 7.86 | -8.40 | -8.40 | 1.52 | 11.73 | 0.0916 | -- | 6.26 | 186,989.70 | -50.61 | -21.88 | -54.64 | -23.30 | 96.49 | 99.63 | -552.52 | -131.50 | -- | -- | 0.00 | -- | 1,024.84 | -0.8606 | -1.63 | -- | -28.01 | -- |
Aurinia Pharmaceuticals Inc | 191.41m | -62.56m | 717.96m | 300.00 | -- | 2.01 | -- | 3.75 | -0.4363 | -0.4363 | 1.34 | 2.50 | 0.3953 | 0.6008 | 7.98 | 638,023.30 | -12.92 | -25.97 | -14.63 | -28.24 | 88.78 | -- | -32.69 | -137.64 | 5.05 | -- | 0.1843 | -- | 30.95 | 227.90 | 27.88 | -- | 57.11 | -- |
Cogent Biosciences Inc | 0.00 | -212.17m | 722.84m | 164.00 | -- | 3.61 | -- | -- | -2.47 | -2.47 | 0.00 | 4.42 | 0.00 | -- | -- | 0.00 | -57.40 | -49.53 | -62.27 | -54.94 | -- | -- | -- | -1,684.44 | -- | -- | 0.00 | -- | -- | -- | -37.20 | -- | 38.48 | -- |
SS Innovations International Inc | 5.88m | -20.94m | 725.58m | 239.00 | -- | 50.74 | -- | 123.40 | -0.1293 | -0.1293 | 0.04 | 0.0838 | 0.3939 | -- | 2.53 | 24,601.30 | -140.31 | -161.38 | -253.40 | -449.76 | 12.13 | -79.79 | -356.17 | -495.77 | 1.30 | -52.51 | 0.2963 | -- | -- | -- | -846.31 | -- | 159.31 | -- |
Arcturus Therapeutics Holdings Inc | 124.53m | -107.30m | 734.06m | 180.00 | -- | 2.78 | -- | 5.89 | -4.02 | -4.02 | 4.66 | 9.81 | 0.2799 | -- | 2.08 | 691,811.10 | -24.12 | -19.66 | -31.37 | -24.90 | -- | -- | -86.16 | -77.55 | -- | -- | 0.00 | -- | -19.03 | 60.31 | -417.95 | -- | 14.44 | -- |
National Research Corporation | 147.42m | 30.36m | 741.45m | 435.00 | 24.96 | -- | 20.41 | 5.03 | 1.24 | 1.24 | 6.02 | -- | 1.16 | -- | 11.56 | 338,896.60 | 23.80 | 26.25 | 35.67 | 36.77 | 62.29 | 63.20 | 20.60 | 23.95 | -- | 132.00 | 0.5325 | 55.45 | -1.97 | 4.42 | -2.58 | 0.6695 | 21.45 | -5.29 |
Disc Medicine Inc | 0.00 | -80.60m | 750.54m | 74.00 | -- | 2.22 | -- | -- | -3.37 | -3.37 | 0.00 | 13.69 | 0.00 | -- | -- | 0.00 | -26.96 | -- | -28.13 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -63.22 | -- | -- | -- |
CARGO Therapeutics Inc | 0.00 | -98.15m | 751.55m | 116.00 | -- | 1.94 | -- | -- | -2.37 | -2.37 | 0.00 | 9.84 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -139.67 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Avidity Partners Management LPas of 22 Jan 2024 | 2.72m | 9.26% |
Fairmount Funds Management LLCas of 22 Jan 2024 | 2.58m | 8.79% |
RA Capital Management LPas of 01 Apr 2024 | 2.33m | 7.95% |
Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 2.22m | 7.56% |
Octagon Capital Advisors LPas of 31 Dec 2023 | 554.00k | 1.89% |
HSBC Portf�y Y�netim ASas of 29 Mar 2024 | 539.00k | 1.84% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 535.42k | 1.82% |
Tang Capital Management LLCas of 31 Dec 2023 | 504.24k | 1.72% |
Nantahala Capital Management LLCas of 31 Dec 2023 | 328.43k | 1.12% |
Susquehanna Financial Group LLLPas of 31 Mar 2024 | 205.49k | 0.70% |